glp-1 washington ad war leads to lawsuit by Novo Nordisk, claiming Eli Lilly misleads Washington DC - CMWL

Some orthopedic surgeons may perceive the growing use of GLP-1 receptor agonists as a potential threat to their practice, fearing that widespread weight loss could reduce the volume of patients requiring joint replacements

For Ozempic pens, the volume delivered varies by pen strength: For the 2 mg/1.5 mL pen (1.34 mg/mL): 0.25 mg dose = 0.19 mL 0.5 mg dose = 0.37 mL For the 4 mg/3 mL pen (1.34 mg/mL): For the 8 mg/3 mL pen (2.67 mg/mL): For Wegovy single-dose pens, each pen is designed to deliver its entire contents as one dose

Gastric bypass surgery enhances glucagon-like Peptide 1-stimulated postprandial insulin secretion in humans

and was an expert witness for GlaxoSmithKline